| Arcadia Medical Associates Pa | |
|
425 Nursing Home Dr Arcadia FL 34266 | |
| (863) 993-2966 | |
| (863) 494-5491 |
| Full Name | Arcadia Medical Associates Pa |
|---|---|
| Speciality | Internal Medicine |
| Location | 425 Nursing Home Dr, Arcadia, Florida |
| Authorized Official Name and Position | Wael Alokeh (OWNER) |
| Authorized Official Contact | 8639932966 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Arcadia Medical Associates Pa Po Box 2020 Arcadia FL 34265-2020 Ph: (863) 993-2966 | Arcadia Medical Associates Pa 425 Nursing Home Dr Arcadia FL 34266 Ph: (863) 993-2966 |
| NPI Number | 1891980215 |
|---|---|
| Provider Enumeration Date | 09/10/2007 |
| Last Update Date | 06/22/2023 |
| Medicare PECOS PAC ID | 6800803289 |
|---|---|
| Medicare Enrollment ID | O20060309000193 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891980215 | NPI | - | NPPES |
| Provider Name | Michael Gallina |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1841279486 PECOS PAC ID: 0042124828 Enrollment ID: I20031117000186 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Wael Alokeh |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1679545362 PECOS PAC ID: 3072520451 Enrollment ID: I20060310000090 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Jennifer Alokeh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497998686 PECOS PAC ID: 5698824407 Enrollment ID: I20090528000181 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Bassam Altajar |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1013945815 PECOS PAC ID: 1456495399 Enrollment ID: I20100216000799 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Joseph N Pace |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1205823838 PECOS PAC ID: 6800923509 Enrollment ID: I20100429000503 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Robert J Subbiondo |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1467449017 PECOS PAC ID: 7012961154 Enrollment ID: I20100610000164 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Joseph Brannen Ganey |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1528071248 PECOS PAC ID: 7012987332 Enrollment ID: I20100719000225 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Lawrence J Elliott |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1689670010 PECOS PAC ID: 5193841104 Enrollment ID: I20100928000524 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Paula Ann Bedo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1104869668 PECOS PAC ID: 1254525371 Enrollment ID: I20101103000282 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Dipesh Deray |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1427382407 PECOS PAC ID: 5395983035 Enrollment ID: I20130607000366 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | John Fernandez |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1992198709 PECOS PAC ID: 0941529473 Enrollment ID: I20150506000016 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Tammy Baker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700260346 PECOS PAC ID: 8123337847 Enrollment ID: I20151020002999 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Samir Dawod Rajiha |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1053751149 PECOS PAC ID: 5799090130 Enrollment ID: I20160420002329 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Walid Farahat Tanyous |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1366670408 PECOS PAC ID: 2062792203 Enrollment ID: I20161206000941 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Anna Christina Figueroa |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023527959 PECOS PAC ID: 5193083111 Enrollment ID: I20171221001236 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Alana Hoffman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295231827 PECOS PAC ID: 4587928452 Enrollment ID: I20180430001656 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Christopher Corriveau |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811479728 PECOS PAC ID: 4486908423 Enrollment ID: I20181112000204 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Jordan Panicco |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1770998478 PECOS PAC ID: 8426328709 Enrollment ID: I20181119001532 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Deborah Zolkos |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1659845980 PECOS PAC ID: 0648518738 Enrollment ID: I20190215000239 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Jaime A Baquero |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1639176993 PECOS PAC ID: 3072575380 Enrollment ID: I20200330003460 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Jessica Lee Betancourt |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1639550619 PECOS PAC ID: 2062834773 Enrollment ID: I20200625003264 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Enzo Andre Nicosia |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1972008852 PECOS PAC ID: 5890104525 Enrollment ID: I20210511000652 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Nina Lundberg |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1902200702 PECOS PAC ID: 8628366580 Enrollment ID: I20210519002948 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Zorana Grujic |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1174009989 PECOS PAC ID: 1052655115 Enrollment ID: I20210630003858 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Wesley Hendricks |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1598077703 PECOS PAC ID: 2062654551 Enrollment ID: I20210805002024 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Alexander Paul Troum |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1629425533 PECOS PAC ID: 7012244247 Enrollment ID: I20220518000647 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Antonio Edoardo Lubrano Heinsen |
|---|---|
| Provider Type | Practitioner - Endocrinology |
| Provider Identifiers | NPI Number: 1801317367 PECOS PAC ID: 7012395106 Enrollment ID: I20220601002196 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Aaron Rene Allick Douen |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1013577998 PECOS PAC ID: 5193181303 Enrollment ID: I20230512002525 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Kevin Courtney Kemp |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1043818784 PECOS PAC ID: 7214393271 Enrollment ID: I20230517000421 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Frank Oliver |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1477113934 PECOS PAC ID: 3274918313 Enrollment ID: I20230817001144 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Georgia Ann Varner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316628951 PECOS PAC ID: 4183087489 Enrollment ID: I20230905002365 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
| Provider Name | Jessica Ann Gunderson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174386379 PECOS PAC ID: 5890130108 Enrollment ID: I20240227000685 |
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
News Archive
Helen M. Genova, PhD, of Kessler Foundation, was awarded a two-year K18 grant for $266,988 from the NIH's National Institute of Mental Health - the NIMH Career Enhancement Award to Advance Autism Services Research for Adults and Transition-Age Youth.
White House advisers believe the strategy of blanketing the airwaves with President Obama's live speeches has been an effective one in gaining a foothold in the health care debate, Roll Call reports. After a particularly media-heavy month for the president, critics have said Obama is "overexposed." His aides, however, call that "dominating news cycles," a welcome change after an August in which harsh criticism of the president's plans stole headlines.
Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.
Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.
› Verified 6 days ago
Family Care Medical Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 819 N Mills Ave, Arcadia, FL 34266 Phone: 863-491-2277 Fax: 863-491-3077 | |
Arcadia Int Medicine P A Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 830 N Mills Ave, Arcadia, FL 34266 Phone: 863-494-6599 Fax: 863-494-5467 | |
Community Care Family Healthcare Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1148 E Gibson St, Build C, Arcadia, FL 34266 Phone: 863-494-6222 Fax: 863-494-3227 | |
Twin Rivers Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 888 N Robert Ave, Arcadia, FL 34266 Phone: 863-494-8401 Fax: 863-993-7622 | |
Catalyst Walk-in Clinic Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1707 East Oak Street, Arcadia, FL 34266 Phone: 863-448-9242 Fax: 863-491-0760 | |
Family Care Medical Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 819 N Mills Ave, Arcadia, FL 34266 Phone: 863-491-2277 Fax: 863-491-3077 | |
Ama Arcadia Pharmacy Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 425 Nursing Home Dr, Arcadia, FL 34266 Phone: 863-993-2966 Fax: 863-494-5491 |